This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $299,969 to L2 Diagnostics LLC to conduct research on the mosquito salivary protein AgBr1 as a vaccine candidate against chikungunya virus. The research aims to evaluate different AgBr1 vaccine formulations, including recombinant protein and mRNA-LNP, to assess their protective effects against chikungunya transmission in mouse models. This work builds on prior findings that AgBr1 vaccination can enhance immunity and protection against other mosquito-borne viruses like Zika and West Nile. The ultimate goal is to develop a universal vaccine against multiple mosquito-borne diseases. The award period runs from Jul 17, 2024 to Jun 30, 2026.
Generated 1/28/25, 7:50 AM